Singapore markets closed
AIRLINES

Omicron’s rapid spread shreds budding recovery in air travel

CSL Limited (CMXHF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
208.20+2.70 (+1.31%)
At close: 03:35PM EST
Full screen
Trade prices are not sourced from all markets
Previous close205.50
Open208.00
BidN/A x N/A
AskN/A x N/A
Day's range208.00 - 208.20
52-week range187.25 - 239.41
Volume63
Avg. volume444
Market cap94.871B
Beta (5Y monthly)0.11
PE ratio (TTM)39.96
EPS (TTM)5.21
Earnings dateN/A
Forward dividend & yield2.17 (1.04%)
Ex-dividend date02 Sep 2021
1y target estN/A
  • Reuters

    Australia's CSL in exclusive talks for $7 billion buyout of Swiss Vifor Pharma - report

    After discussing a potential deal since March, the companies were now in advanced talks and CSL, the world's largest maker of blood plasma treatments, was carrying out due diligence on the Swiss firm, according to reports in The Australian Financial Review and The Australian. Both Vifor Pharma and CSL said in separate statements that they will not comment on the speculation. Morgan Stanley analysts said in a research note that CSL may be seeking diversification because blood plasma collections - where it pays people to give blood, which it then converts to treatments - remained depressed due to COVID-19 restrictions.

  • CNW Group

    The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of Age

    Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published absolute efficacy data on the company's cell-based quadrivalent influenza vaccine (QIVc) from a randomized controlled trial (RCT) which met its primary endpoint.1 The study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of

  • CNW Group

    Seqirus Ready to Reinforce Canada's Influenza Pandemic Preparedness Plans

    Health Canada's Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic PartnerMONTREAL, March 23, 2021 /PRNewswire/ -- Seqirus, a world leader in influenza vaccines and pandemic response, announced today that following Health Canada's approval of FOCLIVIA® (adjuvanted, egg-based A strain H5N1 pandemic influenza vaccine), the Company is ready to fulfil its role in Canada's influenza pandemic preparedness plans.Seqirus Canada is an influenza pandemic vaccine partner to the Canadian Government through the Public Health Agency of Canada (PHAC).